期刊文献+

苯扎贝特治疗高三酰甘油血症的疗效观察 被引量:1

Effects of Bezafibrate on hypertriglyceridemia
下载PDF
导出
摘要 目的探讨苯扎贝特治疗高三酰甘油血症的疗效及安全性。方法连续入选门诊及住院高三酰甘油血症患者324例,采用随机双盲法分为苯扎贝特组和空白对照组,每组各162例,分别口服苯扎贝特0.2 g,3次/d和淀粉空白片0.2 g,3次/d,治疗1~3个月。结果苯扎贝特组治疗1个月后,血三酰甘油较治疗前下降了42.5%,总胆固醇下降了14.9%,高密度脂蛋白胆固醇升高了31.2%,低密度脂蛋白胆固醇下降了27.0%,餐后4 h三酰甘油下降了38.5%(均为P<0.01);而对照组治疗前后上述各项指标差异均无统计学意义(均为P>0.05)。治疗3个月后,苯扎贝特组患者血脂的达标率较治疗1个月后进一步提高。治疗过程中,苯扎贝特组患者的血压、血糖未见升高。结论苯扎贝特具有改善血脂的作用,尚不升高血压、血糖,有较好的安全性。
出处 《中国心血管杂志》 2012年第6期449-451,共3页 Chinese Journal of Cardiovascular Medicine
关键词 苯扎贝特 三酰甘油 血脂异常 血压 血糖 Bezafibrate Triglyceride Dyslipidemias Blood pressure Blood glucose
  • 相关文献

参考文献10

  • 1李明龙,黄冰,梁波,陈立勇,杨萍.老年糖尿病患者脂肪餐后甘油三酯的变化及其对血管内皮功能的影响[J].中华老年医学杂志,2006,25(7):516-518. 被引量:8
  • 2Goldenberg I, Benderly M, Goldbourt U; BIP Study Group. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coil Cardiol, 2008, 51 : 459-465.
  • 3Arcavi L, Behar S, Caspi A, et al. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. Am Heart J, 2004, 147: 239-245.
  • 4Hrebfcek J. PPARs: the role in glucose and lipid homeostasis, insulin resistance and atherosclerosis. Cesk Fysiol, 2004, 53 : 4- 16.
  • 5Tenenbaum A, Motro M, Fisman EZ. Dualand and pan- peroxisome proliferator-activated receptors (PPAR) eo-agonism : the bezafibrate lessons. Cardiovasc Diabetol, 2005, 16 : 14.
  • 6Nagasawa T,/nadaY, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR8 agonist, on development of steatohepatitis in mice fed amethionine-and choline-deficient diet. Eur J Pharmacol, 2006, 536: 182-191.
  • 7骆雷鸣,朱启伟,朱兵,李妍涵,顾洁,李溪远,马琴,曾强,杨雪,吴红梅,毛利,叶平.国产苯扎贝特对高三酰甘油血症脂代谢及糖代谢影响的研究[J].中国实用内科杂志,2009,29(4):350-353. 被引量:12
  • 8叶平,苏工,张铖.苯扎贝特对高甘油三酯血症并高血压患者炎性细胞因子和血压的影响[J].解放军医学杂志,2005,30(3):216-218. 被引量:5
  • 9张慧平,孙福成,王抒.高密度脂蛋白与动脉粥样硬化和冠心病[J].中国动脉硬化杂志,2004,12(6):733-736. 被引量:22
  • 10Kim JI, Tsujino T, Fujioka Y, et al. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res, 2003, 26: 307-313.

二级参考文献60

  • 1刘乃丰.氧化修饰LDL在动脉粥样硬化发生中的作用[J].中国病理生理杂志,1994,10(1):104-107. 被引量:15
  • 2田庆印.氧化修饰脂蛋白与动脉粥样硬化[J].中国动脉硬化杂志,1996,4(2):149-153. 被引量:15
  • 3方微 张慧信 王绿娅.粘附分子、炎症与动脉粥样硬化.中国动脉硬化杂志,2002,10(39):64-64.
  • 4Inaba T,Yagyu H, Itabashi N, et al. Cholesterol reduction and ather- osclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice[ J]. Hypertens Res,2008,31 (5) :999 - 1005.
  • 5Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease [ J ]. Circulation ,2004,109:2197 - 2202.
  • 6Arcavi L, Behar S, Caspi A, et al. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study[ J]. Am Heart J ,2004,147 ( 2 ) :239 - 245.
  • 7Hrebicek J. PPARs:the role in glucose and lipid homeostasis,insulin resistance and atherosclerosis[ J]. Cesk Fysiol,2004,53 ( 1 ) : 4-16.
  • 8Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors ( PPAR ) co-agonism : the bezafibrate lessons [ J ]. C ardiovasc Diabetol, 2005,16 ( 4 ) : 14.
  • 9Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet European[ J]. J Pharmacology,2006,536( 1 -2) :182 - 191.
  • 10Nakano S, Inada Y, Masuzaki H, et al. Bezafibrate regulates the expression and enzyme activity of 11 β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 333-L1 adipocytes [ J]. Am J Physiol Endocrinol Metab,2007,292(4) :E1213 -E1222.

共引文献43

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部